Ausgabe 1/2018
The Microbiome and Neurologic Disease
Inhalt (21 Artikel)
The Microbiome and Neurologic Disease: Past and Future of a 2-Way Interaction
Javier Ochoa-Repáraz, Lloyd H. Kasper
Gut Microbiota and the Neuroendocrine System
Aitak Farzi, Esther E. Fröhlich, Peter Holzer
Microbiome, Immunomodulation, and the Neuronal System
Eric Marietta, Irina Horwath, Veena Taneja
The Microbiome–Gut–Behavior Axis: Crosstalk Between the Gut Microbiome and Oligodendrocytes Modulates Behavioral Responses
Achilles Ntranos, Patrizia Casaccia
Anxiety, Depression, and the Microbiome: A Role for Gut Peptides
Gilliard Lach, Harriet Schellekens, Timothy G. Dinan, John F. Cryan
Gut Microbiota Are Disease-Modifying Factors After Traumatic Spinal Cord Injury
Kristina A. Kigerl, Klauss Mostacada, Phillip G. Popovich
Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
M. C. Buscarinu, S. Romano, R. Mechelli, R. Pizzolato Umeton, M. Ferraldeschi, A. Fornasiero, R. Reniè, B. Cerasoli, E. Morena, C. Romano, N. D. Loizzo, R. Umeton, M. Salvetti, G. Ristori
The Gut Microbiome in Neuromyelitis Optica
Scott S. Zamvil, Collin M. Spencer, Sergio E. Baranzini, Bruce A. C. Cree
The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings
Helen Tremlett, Emmanuelle Waubant
The “Gut Feeling”: Breaking Down the Role of Gut Microbiome in Multiple Sclerosis
Samantha N. Freedman, Shailesh K. Shahi, Ashutosh K. Mangalam
The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the “MS Microbiome”
Anne-Katrin Pröbstel, Sergio E. Baranzini
Microbiota Signaling Pathways that Influence Neurologic Disease
Laura M. Cox, Howard L. Weiner
Endovascular Ischemic Stroke Models in Nonhuman Primates
Di Wu, Ankush Chandra, Jian Chen, Yuchuan Ding, Xunming Ji
S-Adenosyl Methionine and Transmethylation Pathways in Neuropsychiatric Diseases Throughout Life
Jin Gao, Catherine M. Cahill, Xudong Huang, Joshua L. Roffman, Stefania Lamon-Fava, Maurizio Fava, David Mischoulon, Jack T. Rogers
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial
Jordi Bruna, Sebastián Videla, Andreas A. Argyriou, Roser Velasco, Jesús Villoria, Cristina Santos, Cristina Nadal, Guido Cavaletti, Paola Alberti, Chiara Briani, Haralabos P. Kalofonos, Diego Cortinovis, Mariano Sust, Anna Vaqué, Thomas Klein, Carlos Plata-Salamán
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA
Tjalf Ziemssen, Michael Lang, Björn Tackenberg, Stephan Schmidt, Holger Albrecht, Luisa Klotz, Judith Haas, Christoph Lassek, Jennie Medin, Christian Cornelissen
Chronic Fluoxetine Induces Activity Changes in Recovery From Poststroke Anxiety, Depression, and Cognitive Impairment
Faranak Vahid-Ansari, Paul R. Albert
iTRAQ-Based Quantitative Proteomics Reveals the New Evidence Base for Traumatic Brain Injury Treated with Targeted Temperature Management
Shi-Xiang Cheng, Zhong-Wei Xu, Tai-Long Yi, Hong-Tao Sun, Cheng Yang, Ze-Qi Yu, Xiao-Sa Yang, Xiao-Han Jin, Yue Tu, Sai Zhang